ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Bone Metastases

Bone Metastases

Enhanced control of osseous metastases with both systemic life-extending therapies and bone-support medications has meaningful clinical impact for prostate cancer patients.

Here we discuss the efficacy and safety of zoledronic acid, denosumab, enzalutamide, abiraterone, and radium-223 and review the available data regarding the cost of denosumab compared with that of zoledronic acid.

Denosumab used as an adjuvant therapy in postmenopausal breast cancer patients on aromatase inhibitor therapy cut the risk of fractures in half.

A study showed that prostate cancer patients with bone metastases could have a long-term response to ADT and an acceptable quality of life for 10 or more years.

The appearance of bone metastases on FDG PET/CT was influenced by breast cancer histology, with non-FDG-avid lesions more common in invasive lobular carcinoma patients.

In a mouse model, researchers found that TRAIL-R2 inhibition prevented bone metastases, suggesting a possible therapeutic strategy for breast cancer patients.

In a recently published study, patients who did not respond to initial radiation or re-irradiation of symptomatic bone metastases had significantly higher urinary markers of bone turnover at baseline and follow-up.

Pages

Subscribe to Bone Metastases on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.